Go Pro
→ The trade I’ve been waiting for since 2011 (From Traders Agency) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$34.10
+0.4%		$24.23
$9.75
▼
$41.14
$3.80B-0.133.69 million shs885,478 shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$270.56
-0.2%		$257.84
$186.05
▼
$282.15
$16.88B0.35534,748 shs723,460 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$74.84
-0.8%		$80.74
$48.78
▼
$93.42
$14.63B0.972.04 million shs1.54 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.01
-0.2%		$55.07
$33.76
▼
$59.72
$14.62B0.422.16 million shs1.58 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
0.00%-1.84%+40.97%+156.01%+246.54%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+9.14%+8.29%+28.56%+35.27%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-2.30%-9.61%+10.69%+44.37%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+8.37%+13.05%+11.97%+59.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$34.10
+0.4%		$24.23
$9.75
▼
$41.14
$3.80B-0.133.69 million shs885,478 shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$270.56
-0.2%		$257.84
$186.05
▼
$282.15
$16.88B0.35534,748 shs723,460 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$74.84
-0.8%		$80.74
$48.78
▼
$93.42
$14.63B0.972.04 million shs1.54 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.01
-0.2%		$55.07
$33.76
▼
$59.72
$14.62B0.422.16 million shs1.58 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
0.00%-1.84%+40.97%+156.01%+246.54%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+9.14%+8.29%+28.56%+35.27%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-2.30%-9.61%+10.69%+44.37%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+8.37%+13.05%+11.97%+59.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$36.507.04% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.05
Buy$310.0514.60% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$101.5335.66% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.07-15.16% Downside

Current Analyst Ratings Breakdown

Latest AMLX, ASND, BBIO, and EXEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/2/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$304.00 ➝ $312.00
9/1/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$96.00 ➝ $110.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$275.00 ➝ $273.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$327.00
9/1/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$333.00 ➝ $330.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$328.00 ➝ $326.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$345.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$306.00 ➝ $304.00
(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/A$2.15 per shareN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M20.72N/AN/A$26.78 per share10.10
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M29.14N/AN/A($12.81) per share-5.84
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.30$3.03 per share19.49$7.44 per share7.93
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.43N/AN/AN/AN/A-52.92%-48.53%11/5/2026 (Estimated)
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8920.9930.40N/A70.99%32.54%7.71%11/11/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.5615.861.7635.33%42.17%31.76%11/3/2026 (Estimated)

Latest AMLX, ASND, BBIO, and EXEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/6/2026Q2 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3609-$0.39-$0.0291-$0.39N/AN/A
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$1.022.98%N/AN/A N/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
12.12
12.12
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10.90%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
200111.42 million99.28 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable

Recent News About These Companies

Q4 Earnings Forecast for Exelixis Issued By Zacks Research
September 6 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005716
Exelixis, Inc. $EXEL Shares Sold by Three Seasons Wealth LLC
September 5 at 5:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-exelixis-inc-exel-shares-sold-by-three-seasons-wealth-llc-2026-09-05/
IBD Stock Of The Day Exelixis Hits Earnings Snag — And Then Breaks Out
September 4 at 1:31 PM  |  investors.comhttps://www.investors.com/research/ibd-stock-of-the-day/exelixis-stock-break-out-second-quarter-2026/?src=A00220&yptr=yahoo
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
September 4 at 12:37 PM  |  zacks.comhttps://www.zacks.com/stock/news/2985336/exelixis-exel-up-13-3-since-last-earnings-report-can-it-continue?cid=cs-stocknewsapi-ft-realtime_blog-2985336
What is Zacks Research's Estimate for Exelixis Q4 Earnings?
September 4 at 6:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-zacks-researchs-estimate-for-exelixis-q4-earnings-2026-09-04/
Exelixis (NASDAQ:EXEL) Reaches New 52-Week High Following Analyst Upgrade
September 4 at 4:00 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003205
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
September 3 at 10:41 AM  |  zacks.comhttps://www.zacks.com/stock/news/2984350/exelixis-exel-is-a-top-ranked-value-stock-should-you-buy?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_value_score-2984350
Exelixis (NASDAQ:EXEL) Stock Rating Upgraded by Zacks Research
September 3 at 6:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-exelixis-nasdaq-exel-stock-rating-upgraded-by-zacks-research-2026-09-03/
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Position in Exelixis, Inc. $EXEL
September 3 at 5:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-decreases-stock-position-in-exelixis-inc-exel-2026-09-03/
Cancer stock breaks out to highs; key FDA action on watch
September 2, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/cancer-stock-breaks-out-to-highs-key-fda-action-on-watch/ar-AA2bqUaD
Exelixis (NASDAQ:EXEL) Sets New 12-Month High - Still a Buy?
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-exelixis-nasdaq-exel-sets-new-12-month-high-still-a-buy-2026-09-02/
Exelixis, Inc. $EXEL Shares Sold by Corient Private Wealth LP
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-exelixis-inc-exel-shares-sold-by-corient-private-wealth-lp-2026-09-02/
Exelixis, Inc. (NASDAQ:EXEL) Receives $50.07 Average PT from Analysts
September 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30997883
Cancer Drug Patent Claims Upheld by CAFC
September 1, 2026  |  ipwatchdog.comI
Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data
September 1, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4942079-exelixis-hold-zanzalintinib-subpopulation-miss-and-stellar-304-data-2nd-half-2026
Exelixis: 'Hold' On Zanzalintinib Subpopulation Miss And STELLAR-304 H2 2026 Data
September 1, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4942079-exelixis-hold-zanzalintinib-subpopulation-miss-and-stellar-304-data-2nd-half-2026?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Exelixis Wins Appeal in Patent Case Against MSN Laboratories
September 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/exelixis-wins-appeal-patent-case-192510333.html
Corient Private Wealth LP Takes $4.32 Million Position in Exelixis, Inc. $EXEL
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-takes-432-million-position-in-exelixis-inc-exel-2026-09-01/
Exelixis Secures Key Patent Victory, Extends Exclusivity
August 31, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/exelixis-secures-key-patent-victory-extends-exclusivity?utm_source=marketbeat.com&utm_medium=referral
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
August 31, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260831878873/en/Exelixis-Announces-Update-on-Patent-Litigation-Trial-Appeal-with-MSN-Laboratories/
Jefferies Financial Group Inc. Lowers Position in Exelixis, Inc. $EXEL
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jefferies-financial-group-inc-lowers-position-in-exelixis-inc-exel-2026-08-31/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$34.10 +0.14 (+0.41%)
As of 09/4/2026 04:00 PM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$270.56 -0.56 (-0.21%)
As of 09/4/2026 04:00 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$74.84 -0.57 (-0.76%)
As of 09/4/2026 04:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$59.01 -0.12 (-0.20%)
As of 09/4/2026 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas